Report Contents Jump to any section in the series
- Introduction →
- Definitions And Scope →
- Executive Summary →
- Key Trends →
- Market Value →
- Legislation and Regulation →
- Consumer Attitudes →
- Healthcare Providers’ Attitudes →
- Spotlight On Health →
- Psychedelics – Timeline of Key Developments →
- Countries to Watch →
- Psychedelic Profiles →
- Key Psychedelics Deep Dive →
- Other Psychedelics of Note →
- Psychedelics as Medicine: Potential Therapies →
- Psychedelics and Technology →
- Psychedelics Per Country →
- Psychedelics and The Law →
- Patents and Intellectual Property →
- Therapy Practitioners →
- Psychedelic Research →
- Glossary →
International control under the United Nations
The international regulation of psychedelics is primarily governed by the United Nations Convention on Psychotropic Substances, which provides a framework for the global control of substances that affect brain function and can alter mood, awareness, cognition, feelings, or behaviour.
Under this framework, substances are categorised into four schedules (I–IV) based on perceived harm and medical utility. Substances considered to have the lowest risk and recognised medical value are placed in Schedule IV, while those deemed to have no accepted medical use and the highest potential for harm are classified under Schedule I. Some substances may remain unlisted if no significant harm is perceived, as is the case with caffeine.
Psychedelics including psilocybin, MDMA, DMT, and LSD are classified as Schedule I substances under the UN convention. This reflects the UN’s historical position that these compounds lack accepted medical benefits and pose a high risk, despite growing clinical evidence to the contrary.
By contrast, ketamine occupies a unique regulatory position. It is included on the World Health Organisation’s List of Essential Medicines and is not scheduled as a controlled substance under the UN convention.
Ayahuasca is not explicitly scheduled at the international level. However, its primary psychoactive component, DMT, is classified as a Schedule I substance, meaning that the legal status of ayahuasca often depends on national interpretations and enforcement practices. Many countries have also imposed additional domestic controls on some or all of these substances, resulting in significant jurisdictional variation.
Legal Classification of Psychedelics Across Key Jurisdictions
The legal status of psychedelic substances varies substantially between the United Nations framework, the United States, and Canada, reflecting different regulatory priorities and approaches to risk, medical use, and cultural context.
Summary of classifications
- Psilocybin, LSD, MDMA, DMT, ibogaine, and mescaline (peyote) are generally treated as Schedule I substances under UN conventions.
- Ketamine is not controlled at the UN level and is classified differently across national systems.
- Ayahuasca is not specifically scheduled internationally, though its constituent compounds may be.
- Cannabis occupies an intermediate position, with varying degrees of control depending on jurisdiction.
In the United States, most classical psychedelics remain classified as Schedule I substances, while ketamine is placed in Schedule III, reflecting its accepted medical use. Cannabis remains federally restricted, despite state-level reforms.
In Canada, regulatory treatment is more heterogeneous. Several psychedelics fall under Schedule III, while others remain controlled or subject to exemptions. Ketamine is not controlled, and limited exemptions exist for certain traditional or therapeutic contexts.
Interpreting global regulatory complexity
The divergence between international scheduling, national drug laws, and emerging clinical evidence has created a complex and often inconsistent regulatory landscape. While UN scheduling continues to exert significant influence, a small number of member states are not party to the convention or have acceded with conditions, including provisions recognising the rights of Indigenous peoples to use traditionally significant substances.
As clinical trials advance and regulatory pathways evolve, particularly for compounds such as MDMA and psilocybin, this framework is increasingly under pressure. The gap between legacy drug policy and contemporary medical research remains one of the central regulatory challenges facing the psychedelics sector.
Source: Blossom
Note: A small number of UN member states are not party to the convention, or acceded with specific conditions, including protections for Indigenous and traditional uses.
The international regulation of psychedelics is primarily governed by the United Nations Convention on Psychotropic Substances. Most classical psychedelics, including psilocybin, MDMA, DMT, and LSD, are currently classified as Schedule I substances. This classification historically implies that these compounds have no accepted medical benefits and pose a high risk, although emerging clinical evidence is challenging this position.
Unlike psilocybin or MDMA, ketamine is not scheduled as a controlled substance under the UN convention. Instead, it is included on the World Health Organisation’s List of Essential Medicines, recognising its medical utility. In the United States, it is classified as a Schedule III substance, which acknowledges its accepted medical use and lower potential for abuse compared to Schedule I drugs.
The legal status of Ayahuasca is complex. While the brew itself is not explicitly scheduled at the international level by the UN, its primary psychoactive component, DMT, is a Schedule I substance. Consequently, the legality of Ayahuasca often depends on individual national interpretations and enforcement practices, with some countries offering protections for Indigenous and traditional uses.
No, there are significant variations. In the United States, most classical psychedelics remain federally classified as Schedule I substances, despite some state-level reforms. In Canada, the regulatory approach is more heterogeneous; while many psychedelics are controlled, there are specific exemptions (such as Section 56 exemptions) and distinct scheduling for certain substances, reflecting a different approach to risk and medical use.
The gap between legacy drug policy and contemporary medical research is creating pressure on existing frameworks. As clinical trials advance—particularly for MDMA and psilocybin—regulatory pathways are evolving. High-quality data from these trials is essential for challenging the Schedule I classification, which currently asserts “no accepted medical use,” and for moving these compounds into legal medical frameworks.
